The randomized phaseII study about the skin hazard mitigation in the Erlotinib + oral steroid agent combined therapy and Erlotinib to non-small cell lung cancer patients.
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2016
At a glance
- Drugs Erlotinib (Primary) ; Prednisolone
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 21 Jun 2016 Status changed from recruiting to completed.
- 20 Feb 2012 New trial record